{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:16:35Z","timestamp":1788218195574,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7759\/cureus.115539","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:47:07Z","timestamp":1788216427000},"source":"Crossref","is-referenced-by-count":0,"title":["The Transition From Sunitinib Monotherapy to Modern First-Line Tyrosine Kinase Inhibitor (TKI)-Containing Regimens in Metastatic Clear-Cell Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Sravani","family":"Manda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"","author":"Pandey J","year":"2023","unstructured":"Pandey J, Syed W. Renal Cancer. Pandey J, Syed W (ed): StatPearls Publishing, Treasure Island (FL); 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558975\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153777","article-title":"Tyrosine kinase inhibitors in the treatment of metastasised renal cell carcinoma-future or the past?","volume":"14","author":"Michaelis J","year":"2022","unstructured":"Michaelis J, Grabbert M, Sigle A, et al.. Tyrosine kinase inhibitors in the treatment of metastasised renal cell carcinoma-future or the past?. Cancers (Basel). 2022, 14:10.3390\/cancers14153777","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.230356","article-title":"Advances in the management of renal cell carcinoma","volume":"196","author":"Cardenas LM","year":"2024","unstructured":"Cardenas LM, Sigurdson S, Wallis CJ, Lalani AK, Swaminath A. Advances in the management of renal cell carcinoma. CMAJ. 2024, 196:E235-40. 10.1503\/cmaj.230356","journal-title":"CMAJ"},{"key":"ref4","unstructured":"Renal cell carcinoma overview. (2025). https.\/\/www.pathologyoutlines.com\/topic\/kidneytumormalignantrcc.html."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13179.1","article-title":"Renal cell carcinoma: a review of biology and pathophysiology","volume":"7","author":"Nabi S","year":"2018","unstructured":"Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018, 7:307. 10.12688\/f1000research.13179.1","journal-title":"F1000Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.7.13247","article-title":"Signaling pathways in renal cell carcinoma","volume":"10","author":"Banumathy G","year":"2010","unstructured":"Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010, 10:658-64. 10.4161\/cbt.10.7.13247","journal-title":"Cancer Biol Ther"},{"key":"ref7","article-title":"Kidney cancer","volume":"Version 1","author":"Motzer R","year":"2027","unstructured":"Motzer R, Jonasch E, Agarwal N, et al.. Kidney cancer. NCCN Guidelines. 2027, Version 1:June 3, 2026.","journal-title":"NCCN Guidelines"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri TK","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, et al.. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017, 35:591-7. 10.1200\/JCO.2016.70.7398","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri TK","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, et al.. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018, 94:115-25. 10.1016\/j.ejca.2018.02.012","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0316","article-title":"Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial","volume":"24","author":"George DJ","year":"2019","unstructured":"George DJ, Hessel C, Halabi S, et al.. Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist. 2019, 24:1497-501. 10.1634\/theoncologist.2019-0316","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al.. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021, 384:829-41. 10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer RJ","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, et al.. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019, 380:1103-15. 10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab\u00a0+ axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri TK","year":"2025","unstructured":"Choueiri TK, Penkov K, Uemura H, et al.. Avelumab\u00a0+ axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. 2025, 36:387-92. 10.1016\/j.annonc.2024.12.008","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini BI","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al.. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019, 380:1116-27. 10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer RJ","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, et al.. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024, 42:1222-8. 10.1200\/JCO.23.01569","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00343-2","article-title":"First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial","volume":"26","author":"Zhou A","year":"2025","unstructured":"Zhou A, Shen P, Li J, et al.. First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 2025, 26:1145-1157. 10.1016\/S1470-2045(25)00343-2","journal-title":"The Lancet Oncology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae182","article-title":"First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia","volume":"55","author":"Chung HJ","year":"2025","unstructured":"Chung HJ, Kondoh C, Bae WK, et al.. First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. Jpn J Clin Oncol. 2025, 55:406-13. 10.1093\/jjco\/hyae182","journal-title":"Jpn J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh JJ","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, et al.. Renal cell carcinoma. Nat Rev Dis Primers. 2017, 3:17009. 10.1038\/nrdp.2017.9","journal-title":"Nat Rev Dis Primers"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/17562872211053189","article-title":"Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis","volume":"13","author":"Cattrini C","year":"2021","unstructured":"Cattrini C, Messina C, Airoldi C, et al.. Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. Ther Adv Urol. 2021, 13:17562872211053189. 10.1177\/17562872211053189","journal-title":"Ther Adv Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16252","article-title":"Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics","volume":"180","author":"Wang Y","year":"2023","unstructured":"Wang Y, Liu X, Gong L, et al.. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics. Br J Pharmacol. 2023, 180:2937-55. 10.1111\/bph.16252","journal-title":"Br J Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.59262","article-title":"Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma","volume":"12","author":"Domaga\u0142a-Haduch M","year":"2016","unstructured":"Domaga\u0142a-Haduch M, Cedrych I, Jasi\u00f3wka M, Niemiec M, Skotnicki P. Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma. Arch Med Sci. 2016, 12:360-4. 10.5114\/aoms.2016.59262","journal-title":"Arch Med Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126467","article-title":"Molecular and functional analysis of sunitinib-resistance induction in human renal cell carcinoma cells","volume":"22","author":"Rausch M","year":"2021","unstructured":"Rausch M, Rutz A, Allard PM, et al.. Molecular and functional analysis of sunitinib-resistance induction in human renal cell carcinoma cells. Int J Mol Sci. 2021, 22:10.3390\/ijms22126467","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506301-the-transition-from-sunitinib-monotherapy-to-modern-first-line-tyrosine-kinase-inhibitor-tki-containing-regimens-in-metastatic-clear-cell-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:47:08Z","timestamp":1788216428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506301-the-transition-from-sunitinib-monotherapy-to-modern-first-line-tyrosine-kinase-inhibitor-tki-containing-regimens-in-metastatic-clear-cell-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.115539","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}